219.34
+1.99%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Indoco Remedies
Its shares trade on NSE under the ticker INDOCO.NS. It has been listed since 7 January 2005. In the fiscal year to 31 March 2026, it reported revenue of ₹18.45bn and a net loss of ₹987.0m. At that date it held total assets of ₹25.93bn and shareholders' equity of ₹9.39bn.
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm offers medicines in multiple therapeutic categories, such as diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders and primary care medicine. Its products/brands include Cyclopam, Sensodent-K, Karvol Plus, Sensoform, Cital UTI, Kidodent, Rexidin M, Lignox A, Dentogel, Aloja, Homide, Renolen, Noxa, Dexoren - S, Aloja M, ATM, Febrex Plus, Sensodent-KF, SM Fibro, MCBM 69, Cal Aid, Snowdent, Dropizin, Zincoren, Coloferrin, Bfloren, RR Sensoform Dental, Mofloren-D, and Tuspel among others. The firm caters to both domestic and international markets. Its subsidiaries include Xtend Industrial Designers and Engineers Pvt Ltd, Indoco Remedies Czech sro, and Indoco Remedies UK Limited.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Jan 2005
- Employees
- 6,101
- Website
- indoco.com ↗
Leadership
Pay as last reported
- Mr. Suresh KareNon-Executive Non-Independent Chairman of the Board, since 2023₹9.9m
- Ms. Aditi PanandikarChief Executive Officer, Managing Director, Executive Director, since 2004₹85.4m
- Mr. Pramod GhorpadeChief Financial Officer₹17.4m
- Mr. Ramanathan HariharanCompliance Officer, Company Secretary, Head - Legal₹5.5m
- Mr. Sundeep BambolkarJoint Managing Director, Executive Director, since 2004₹75.5m
- Dr. Anand NadkarniNon-Executive Non-Independent Director₹360,000
- Mr. Abhijit GoreIndependent Non-Executive Director₹460,000
- Dr. Vasudha KamatIndependent Non-Executive Director₹500,000
- Mr. Ajay MulgaokarAdditional Non-Executive Independent Director
- Mr. Satish ShenoyAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 43
- Social
- 83
- Governance
- 69
- Direct emissions (scope 1)
- 14,786.81 t
- Energy emissions (scope 2)
- 36,554.03 t
- Women in the workforce
- 8.2475%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company manufactures both formulations and active pharmaceutical ingredients.
- Its products cover multiple therapeutic categories like cardiology and diabetes.
- The firm serves both domestic and international markets effectively.
Weaknesses
- The source description is explicitly treated as untrusted facts.
- Specific financial metrics and growth rates are not provided.
- Operational details beyond employee count are missing from the input.
Opportunities
- Expansion into new therapeutic areas beyond the current portfolio is possible.
- Leveraging subsidiaries in the UK and Czech Republic can aid growth.
- Increasing demand for APIs offers potential for business development.
Threats
- Regulatory changes in international markets may impact operations.
- Competition in the pharmaceutical sector remains intense and dynamic.
- Reliance on untrusted source data poses accuracy risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.